Telix Pharmaceuticals Limited
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christian Behrenbruch
- Full Time Employees
- 1,152
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 55 Flemington Road North Melbourne VIC Australia 3051
- IPO Date
- Nov 14, 2024
- CIK
- 0002007191
- Website
- telixpharma.com
- Similar Companies
- Business
- Telix Pharmaceuticals Limited operates as a commercial-stage biopharmaceutical firm dedicated to advancing and delivering innovative therapeutic and diagnostic radiopharmaceutical agents. The company strategically focuses on a theranostic approach, combining imaging and treatment to precisely target cancers and certain rare conditions. Headquartered in North Melbourne, Australia, Telix maintains significant global operations across the United States, Europe, and Japan. Among its commercial offerings is Illuccix® (gallium-68 gozetotide injection), a key imaging agent utilized for detecting prostate-specific membrane antigen (PSMA)-positive lesions in prostate cancer. Illuccix has secured marketing authorizations in major territories including the United States, Australia, Canada, the United Kingdom, and across Europe. Another recently approved prostate cancer imaging agent, Gozellix®, has commenced its commercial launch in the U.S. Additionally, Telix provides Scintimun® (technetium-99m besilesomab) for imaging osteomyelitis in numerous European countries and Mexico, along with the SENSEI® surgical gamma probe for guided surgery. The company’s robust pipeline includes several late-stage investigational candidates. TLX591, a radio antibody-drug conjugate, is undergoing a pivotal Phase 3 clinical trial for metastatic castration-resistant prostate cancer. For renal (kidney) cancer, the diagnostic agent TLX250-CDx (Zircaix®) received a Complete Response Letter from the U.S. FDA, citing Chemistry, Manufacturing, and Controls deficiencies, despite its prior Breakthrough Therapy designation. TLX250 is being developed as a therapeutic counterpart for kidney cancer. Other significant candidates include TLX101-CDx for brain (glioma) cancer imaging and TLX101 for glioblastoma therapy, alongside TLX592 for targeted alpha therapy in prostate cancer, and TLX090 for metastatic bone pain. Telix also continues to expand its pipeline with novel fibroblast activation protein (FAP)-targeting theranostic agents, initially focusing on bladder cancer. Telix Pharmaceuticals reported strong financial performance in FY2024 with total revenue reaching $783.2 million AUD, predominantly driven by Illuccix sales, and projects FY2025 revenue guidance between $1.18 billion to $1.23 billion AUD ($770 million to $800 million USD). The company, founded in 2015, is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Company News
Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®
Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade
Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume – What’s Next?
Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript
Telix Pharmaceuticals Limited (TLX) M&A Call Transcript
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion
Telix Pharmaceuticals: 'Buy' On Pixclara FDA Approval And TLX591-Tx Part 2 Advancement
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
Telix Appoints David Gill as Chair
Telix Pharmaceuticals: Execution Is The Name Of The Game Here